Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Consun Pharmaceutical Group Ltd. ( (HK:1681) ) has issued an update.
Consun Pharmaceutical Group Ltd. announced that its product, Kidney Repair and Edema Alleviation Granules, has been approved as a Class 2 Protected Product of Traditional Chinese Medicine by the National Medical Products Administration. This approval grants the product a state protection period of seven years, during which other enterprises are prohibited from imitating it. The recognition is expected to support the company’s long-term development and strengthen its market position.
More about Consun Pharmaceutical Group Ltd.
Consun Pharmaceutical Group Ltd. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry with a focus on traditional Chinese medicine. The company, through its subsidiary Guangzhou Consun Pharmaceutical Company Limited, develops and markets products such as the Kidney Repair and Edema Alleviation Granules.
YTD Price Performance: -11.65%
Average Trading Volume: 1,893
Technical Sentiment Signal: Strong Sell
Current Market Cap: €889.6M
For detailed information about 1681 stock, go to TipRanks’ Stock Analysis page.